FDA approves Pfizer's maraviroc HIV treatment

The FDA has granted approval to Pfizer's maraviroc HIV treatment, the drugmaker said today.

Maraviroc, to be marketed under the brand name Selzentry, is expected to be available in the US by the middle of September.

Maraviroc is the first in a class of drugs known as CCR5 antagonists, which works by blocking viral entry into white blood cells, significantly reducing viral load and increasing T-cell counts in treatment-experienced patients infected with a specific type of HIV.

Maraviroc was granted approval under priority review status, which trims time off the standard approval time period. Priority review is usually granted to compounds deemed an advance over existing therapies by the FDA.

Maraviroc hit a bump in the approval process when Pfizer received an approvable letter in June requesting additional information on the drug.
The FDA in April raised concerns that maraviroc could be associated with an increased risk of liver damage, lymphoma and infections.
According to FDA, other developmental CCR5 inhibitors have been shown to increase safety risk issues.

However, Pfizer said its studies showed that maraviroc had no significant effect on the heart and did not increase the incidence of liver problems, cancer or infection compared with other HIV/AIDS drugs.

Analysts have projected sales of maraviroc to reach $500 million by 2011.

You must be a registered member of MMM to post a comment.

Next Article in Careers

Email Newsletters

Investment in healthcare IT stands at an all-time high. The government has spent billions to promote EHR adoption. Yet the physician wish list is a mile long, while hospitals and patients are not where they need to be. To peel back the layers of what we've all been waiting for in the Great Data Capture of the 21st Century, and to review the changes enabling the healthcare data ecosystem to coexist, MM&M presents this e-Book. Click here.

What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.